Skip to main content

Table 1 Overview of most frequently used HDAC inhibitors in the currently recruiting clinical trials

From: HDAC inhibitors in experimental liver and kidney fibrosis

Name

Alternative names

HDACs inhibited

# of clinical trials

Disease

Vorinostat

N1-hydroxy-N8-phenyl-octanediamide, SAHA, Suberoylanilide Hydroxamic Acid, Zolinza

Class I and II

72

Breast Cancer; Ovarian, Fallopian Tube, or Peritoneal Cancer; Prostate Cancer; Soft Tissue Sarcoma; Non-Small Cell Lung Cancer; Solid Tumors with/without HIV infection; Gastric cancer; Multiple Myeloma; Multiple Lymphoid Malignancies, such as Leukemia, Mantle Cell Lymphoma; Large B-Cell Lymphoma; T-Cell Lymphoma; Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Myelodysplastic Syndromes or Myeloproliferative Disorders; Adenoid Cystic Carcinoma; Head and Neck Cancer; Brain Metastasis; Neuroblastoma; Glioma; Glioblastoma Multiforme; Embryonal Tumors of the Central Nervous System; Metastatic Melanoma of the Eye; Graft-Host Disease; Renal Cell Carcinoma

Panobinostat

LBN-589; LBH589; NVP-LBH589

Class I, II and IV

23

Myelodysplastic Syndrome; Metastatic Gastric Cancer; Breast Cancer; B-Cell Lymphoma; Leukemia; Graft-Host Disease; Renal Cell Carcinoma; Hodgkin’s Lymphoma; Lung Cancer; Prostate Cancer; Hepatocellular Carcinoma; T-Cell Lymphoma; Chordoma

Valproic acid

Dipropylacetic acid, VPA, myproic acid, Depakene

Class I

12

Sarcoma; Myelodysplastic Syndrome; Leukemia; Lymphoma; Gliomas; Cervical Cancer; Ovarian cancer

Entinostat

SNDX-275; MS-27-275, MS-275

HDAC1,3

6

Leukemia; Renal Cell Carcinoma; Resected Stage I Non-Small Cell Lung Cancer

Belinostat

PXD101; PX105684

Class I, II and IV

2

Small Cell Lung Carcinoma; Lymphomas

CUDC-101

7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide

multitargeted HDAC, EGFR and HER2 inhibitor

2

Head and Neck Cancers

  1. Table source: clinicaltrials.gov.